灰色市场的针筒里卖的是希望The Gray-Market Syringe Sells Hope
肽这件事,关键不在它有没有效,而在谁有权力把一个未经人体试验的化合物说成"下一个 Ozempic"。报道里 Alexander 说得很直白:社交媒体和灰色市场上卖的合成肽,宣传语是延寿、改善睡眠、增强免疫、护肤、性功能。这些词全部是表达,不是数据。
第三章讲武器化,入口从来不是产品本身,是叙事。Ozempic 成功之后,Cohen 说了一句很准的话:人们由此相信存在一个"神奇的肽世界",别的领域也能复制同样的魔法。这就是认知入口被打开的方式——先有一个被验证的成功,再把它的化学亲戚们打包塞进同一个故事里。GLP-1 是经过大量研究和联邦批准的,BPC-157 不是,但它们在货架上长得很像,在短视频里更像。
真正值得盯的是结构层。HHS reportedly 计划让特殊药房配制某些合成肽,理由之一是 RFK Jr. 对 Joe Rogan 说他是个"big fan"。一个卫生部长在播客上的个人偏好,正在变成一条准入政策。而 BPC-157 同时出现在 FDA 的"可能带来重大安全风险"注射剂清单上。这不是科学在推动监管,是粉丝经济在推动监管。
谁付代价?报道里没有受害者,一个名字都没有。这正是这类新闻的形态:代价还没发生,或者发生了也没被记录。灰色市场的针剂可能成分不对、剂量不对、被细菌污染——Cohen 说的——但这些风险落在谁身上,报道不知道。买这些针的人多半是想要更瘦、更年轻、性功能更好的普通人,他们相信的是影响力博主,不是论文。
专家们的建议是"别用未经批准的注射肽"。这话没错,但它把问题推回给个体,好像这是一次消费选择。可当监管者自己在播客上给某类肽背书,个体的"选择"就已经被结构性地污染了。
报道结尾 Alexander 说,希望支持者"put their money where their mouth is",去做必要的研究。这句话是整篇里最锋利的一句,也是最没人会执行的一句。做研究要花钱、要时间、要失败的风险,卖针只需要一个博主和一个"big fan"。
The question about peptides isn't whether they work. It's who gets to call an untested compound "the next Ozempic." Alexander says it plainly in the report: synthetic peptides sold on social media and the gray market are marketed as longevity, sleep, immunity, skin, sexual function. Those are expressions, not data.
Chapter 3 is about weaponization, and the entry point is never the product. It's the narrative. After Ozempic's success, Cohen nails it: people came to believe there must be a "magical world" of other peptides that could do similar magic elsewhere. That's how a cognitive entrance opens—one validated success, then its chemical cousins get packed into the same story. GLP-1s are heavily researched and federally approved. BPC-157 is not. On a shelf they look alike; in a short video they look identical.
The structural layer is where this gets serious. HHS is reportedly planning to let specialty pharmacies compound certain synthetic peptides, and one stated reason is that RFK Jr. told Joe Rogan he's a "big fan." A health secretary's podcast preference is becoming an access policy. Meanwhile BPC-157 sits on an FDA list of injectables that "may present significant safety risks." This isn't science pushing regulation. It's fandom pushing regulation.
Who pays? The report names no victims. That's the shape of this kind of story: the cost hasn't landed yet, or it landed somewhere no one recorded. Gray-market vials may contain the wrong compound, the wrong dose, bacteria—Cohen's warning—but who absorbs that risk, the report doesn't say. The buyers are ordinary people who want to be thinner, younger, better in bed. They trust influencers, not papers.
The experts' advice—don't use unapproved injectable peptides—is correct, but it pushes the problem back onto the individual, as if this were a consumer choice. When the regulator himself endorses a category on a podcast, the individual's "choice" has already been structurally contaminated.
Alexander closes with a line that's the sharpest in the piece and the least likely to be executed: supporters should put their money where their mouth is and do the studies. Research costs money, time, and the risk of failure. Selling vials costs one influencer and one "big fan."